ArticleJournal of ovarian research2026
Role of BTLA in ovarian cancer and its clinical prognostic significance based on multi-omics analysis.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer (OV) is a highly lethal gynecological malignancy with limited effective biomarkers for prognosis and precision immunotherapy. B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule involved in tumor immune regulation, but its role in OV remains unclear.
methodsTranscriptomic data from The Cancer Genome Atlas (TCGA) were analyzed to evaluate BTLA expression and its potential clinical relevance in OV. Exploratory multivariable Cox regression analysis was performed to examine the association between BTLA expression and patient prognosis. Functional characteristics were investigated through gene set enrichment and variation analyses, protein-protein interaction analysis, and regulatory network construction. Single-cell RNA sequencing (ScRNA-seq) was applied to explore cellular heterogeneity and BTLA-related cell-cell communication. Drug sensitivity analyses and molecular docking were conducted to assess therapeutic relevance. Experimental assays were performed to validate BTLA expression.
resultsBTLA was significantly upregulated in OV tissues compared with normal controls. Higher BTLA expression was associated with patient prognosis in exploratory Cox regression and Kaplan-Meier (KM) analyses. Functional enrichment revealed associations with immune- and tumor-related pathways including epithelial mesenchymal transition (EMT), interleukin-10 signaling, and interferon responses. Single-cell analysis demonstrated BTLA-related transcriptional heterogeneity across cell populations, with epithelial cells showing the highest activity. Drug sensitivity profiling identified differential responses between BTLA expression groups, and molecular docking suggested moderate binding affinity between BTLA and genistein (Vina score = - 6.3 kcal/mol). Experimental validation confirmed increased BTLA expression at both mRNA and protein levels in OV tissues.
conclusionThese findings suggest that BTLA may be involved in the tumor immune microenvironment of OV and may provide preliminary clues as a potential biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.